Diadema Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Diadema Partners’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-214,291	Closed	-$1.73M	–	144
2024 Q4	$1.73M	Buy	+214,291	New	+$1.97M	0.74%	41

Other funds holding ORIC

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Diadema Partners's ORIC Position: Q1 2025 in Review

Diadema Partners sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 214,291 shares — an estimated $1.73M sold.

Diadema Partners first reported a position in ORIC in Q4 2024 and held it in 1 quarter. The position peaked at $1.73M in Q4 2024. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

Diadema Partners reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Diadema Partners sold 214,291 Oric Pharmaceuticals shares in Q1 2025, an estimated $1.73M.
Diadema Partners first reported a position in Oric Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Diadema Partners's Oric Pharmaceuticals position peaked at $1.73M in Q4 2024.
143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.